Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Ligand Pharmaceuticals (LGND) over the last 15 years, with Q3 2025 value amounting to $117.3 million.

  • Ligand Pharmaceuticals' Net Income towards Common Stockholders changed N/A to $117.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year change of. This contributed to the annual value of -$4.0 million for FY2024, which is 14216.22% down from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Net Income towards Common Stockholders stood at $117.3 million.
  • Ligand Pharmaceuticals' Net Income towards Common Stockholders' 5-year high stood at $117.3 million during Q3 2025, with a 5-year trough of -$42.5 million in Q1 2025.
  • Its 5-year average for Net Income towards Common Stockholders is -$33923.1, with a median of -$4.7 million in 2021.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Net Income towards Common Stockholders skyrocketed by 8068.87% in 2021, and later crashed by 13603.29% in 2022.
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Net Income towards Common Stockholders stood at -$2.2 million in 2021, then crashed by 32.75% to -$3.0 million in 2022, then surged by 43.58% to -$1.7 million in 2023, then plummeted by 1767.15% to -$31.1 million in 2024, then soared by 477.23% to $117.3 million in 2025.
  • Its last three reported values are $117.3 million in Q3 2025, $4.8 million for Q2 2025, and -$42.5 million during Q1 2025.